Aytu BioPharma is set to release its fiscal fourth-quarter 2026 results after the U.S. market closes on September 22. The company is expected to report at approximately 4:05 p.m. ET, with investors focused on whether revenue can stabilize and whether losses are beginning to narrow.

Analysts currently expect fourth-quarter revenue of $12.28 million and earnings per share of negative $0.29. The estimates provide a benchmark against which investors will assess the company’s latest operating performance and its trajectory into the next fiscal year.

Revenue Has Fluctuated Through Fiscal 2026

Aytu’s reported revenue has varied throughout the fiscal year. Revenue reached $13.89 million in Q1 2026 before increasing to $15.20 million in Q2. It then declined to $12.41 million in Q3, leaving the company with a lower revenue base heading into the fourth quarter.

The Q4 estimate of $12.28 million is slightly below the $12.41 million reported in the previous quarter. It is also materially below the $15.13 million reported in Q4 2025, indicating that analysts are not currently expecting a return to the revenue levels recorded a year earlier.

Losses Remain the Main Earnings Challenge

Profitability remains a significant issue in the earnings outlook. Aytu reported a loss of $0.08 per share in Q1 2026, followed by a loss of $1.05 in Q2 and $0.53 in Q3. Analysts now expect the fourth-quarter loss to narrow to $0.29 per share.

The expected improvement would represent a smaller loss than the previous quarter, but the company would still remain unprofitable based on the current estimate. Investors may therefore focus on whether the reported results show continued progress toward reducing the earnings deficit.

Recent Results Have Produced Mixed Surprises

Aytu’s recent revenue performance has produced several positive surprises against estimates. Q1 revenue of $13.89 million exceeded the $12.60 million estimate by 10.24%, while Q2 revenue of $15.20 million was 24.85% above the $12.17 million estimate. Q3 revenue of $12.41 million also exceeded its $12.05 million estimate by 2.97%.

However, the earnings record has been less consistent. Q1 EPS of negative $0.08 was better than the estimated negative $0.19, while Q2 EPS of negative $1.05 and Q3 EPS of negative $0.53 came in below their respective estimates.

What Investors May Watch Next

The September 22 release will provide the latest indication of whether Aytu can stabilize revenue while narrowing its losses. Investors may compare actual revenue with the $12.28 million estimate and examine whether the expected loss of $0.29 per share is achieved. The company’s ability to improve profitability while maintaining revenue will be particularly important as investors assess its financial trajectory beyond fiscal 2026.